Cargando…
Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
Aggregation of α-synuclein (αSyn) plays a central role in the pathogenesis of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies (LBs) and Lewy neurites, which consist mainly of aggregated αSyn, are widely observed in the affected regions of patient brains. Except for some fam...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619337/ https://www.ncbi.nlm.nih.gov/pubmed/31333408 http://dx.doi.org/10.3389/fnins.2019.00693 |
_version_ | 1783433915943354368 |
---|---|
author | Ikenaka, Kensuke Suzuki, Mari Mochizuki, Hideki Nagai, Yoshitaka |
author_facet | Ikenaka, Kensuke Suzuki, Mari Mochizuki, Hideki Nagai, Yoshitaka |
author_sort | Ikenaka, Kensuke |
collection | PubMed |
description | Aggregation of α-synuclein (αSyn) plays a central role in the pathogenesis of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies (LBs) and Lewy neurites, which consist mainly of aggregated αSyn, are widely observed in the affected regions of patient brains. Except for some familial forms of PD/DLB, most sporadic PD/DLB patients express the wild-type (WT) αSyn protein without any mutations, and the mechanisms as to how WT αSyn gains the propensity to pathologically aggregate still remains unclear. Furthermore, the mechanisms by which the same αSyn protein can cause different synucleinopathies with distinct phenotypes and pathologies, such as PD, DLB, and multiple system atrophy (MSA), still remain largely unknown. Recently, mutations in the GBA1 gene (encoding glucocerebrosidase), which are responsible for the lysosomal storage disorder Gaucher disease (GD), have been reported to be the strongest risk factor for developing sporadic PD/DLB. We previously demonstrated that glucosylceramide accumulated by GBA1 deficiency promotes the conversion of αSyn into a proteinase K-resistant conformation. Furthermore, decreased glucocerebrosidase activity has also been reported in the brains of patients with sporadic PD/DLB. Moreover, αSyn pathology has also been shown in the brains of lysosomal storage disorder patients, which show glycosphingolipid accumulation. These observations suggest the possibility that altered lipid metabolism and lipid accumulation play roles in αSyn aggregation and PD/DLB pathogenesis. Indeed, several previous studies have demonstrated that lipid interactions affect the conformation of αSyn and induces its oligomerization and aggregation. In this review, we will give an overview of the association between αSyn aggregation and lipid interactions from the viewpoints of the etiology, pathology, and genetics of PD/DLB. We also discuss the distinct species of αSyn aggregates and their association with specific types of synucleinopathies, and introduce our hypothesis that lipid interactions play a role as trans-acting effectors in producing distinct strains of αSyn fibrils. |
format | Online Article Text |
id | pubmed-6619337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66193372019-07-22 Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease Ikenaka, Kensuke Suzuki, Mari Mochizuki, Hideki Nagai, Yoshitaka Front Neurosci Neuroscience Aggregation of α-synuclein (αSyn) plays a central role in the pathogenesis of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies (LBs) and Lewy neurites, which consist mainly of aggregated αSyn, are widely observed in the affected regions of patient brains. Except for some familial forms of PD/DLB, most sporadic PD/DLB patients express the wild-type (WT) αSyn protein without any mutations, and the mechanisms as to how WT αSyn gains the propensity to pathologically aggregate still remains unclear. Furthermore, the mechanisms by which the same αSyn protein can cause different synucleinopathies with distinct phenotypes and pathologies, such as PD, DLB, and multiple system atrophy (MSA), still remain largely unknown. Recently, mutations in the GBA1 gene (encoding glucocerebrosidase), which are responsible for the lysosomal storage disorder Gaucher disease (GD), have been reported to be the strongest risk factor for developing sporadic PD/DLB. We previously demonstrated that glucosylceramide accumulated by GBA1 deficiency promotes the conversion of αSyn into a proteinase K-resistant conformation. Furthermore, decreased glucocerebrosidase activity has also been reported in the brains of patients with sporadic PD/DLB. Moreover, αSyn pathology has also been shown in the brains of lysosomal storage disorder patients, which show glycosphingolipid accumulation. These observations suggest the possibility that altered lipid metabolism and lipid accumulation play roles in αSyn aggregation and PD/DLB pathogenesis. Indeed, several previous studies have demonstrated that lipid interactions affect the conformation of αSyn and induces its oligomerization and aggregation. In this review, we will give an overview of the association between αSyn aggregation and lipid interactions from the viewpoints of the etiology, pathology, and genetics of PD/DLB. We also discuss the distinct species of αSyn aggregates and their association with specific types of synucleinopathies, and introduce our hypothesis that lipid interactions play a role as trans-acting effectors in producing distinct strains of αSyn fibrils. Frontiers Media S.A. 2019-07-03 /pmc/articles/PMC6619337/ /pubmed/31333408 http://dx.doi.org/10.3389/fnins.2019.00693 Text en Copyright © 2019 Ikenaka, Suzuki, Mochizuki and Nagai. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Ikenaka, Kensuke Suzuki, Mari Mochizuki, Hideki Nagai, Yoshitaka Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease |
title | Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease |
title_full | Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease |
title_fullStr | Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease |
title_full_unstemmed | Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease |
title_short | Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease |
title_sort | lipids as trans-acting effectors for α-synuclein in the pathogenesis of parkinson’s disease |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619337/ https://www.ncbi.nlm.nih.gov/pubmed/31333408 http://dx.doi.org/10.3389/fnins.2019.00693 |
work_keys_str_mv | AT ikenakakensuke lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease AT suzukimari lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease AT mochizukihideki lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease AT nagaiyoshitaka lipidsastransactingeffectorsforasynucleininthepathogenesisofparkinsonsdisease |